Additionally, the relationship between IL-17A and accompanying anti-acetylcholine receptor antibody titers show the potential of IL-17 as a biomarker for MG, suggesting that modulating the IL-17/Th17 axis could offer a promising medical strategy. Here, IL17A is linked to myasthenia gravis.